{"id":"NCT04471428","sponsor":"Hoffmann-La Roche","briefTitle":"Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy","officialTitle":"A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-01","primaryCompletion":"2022-09-28","completion":"2025-01-17","firstPosted":"2020-07-15","resultsPosted":"2023-12-20","lastUpdate":"2025-06-12"},"enrollment":366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"Cabozantinib","otherNames":[]},{"type":"DRUG","name":"Atezolizumab","otherNames":["Tecentriq"]},{"type":"DRUG","name":"Docetaxel","otherNames":[]}],"arms":[{"label":"Atezolizumab + Cabozantinib","type":"EXPERIMENTAL"},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and anti-PD-L1/PD-1 antibody, administered concurrently or sequentially.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 24 months","effectByArm":[{"arm":"Docetaxel","deltaMin":10.5,"sd":null},{"arm":"Atezolizumab + Cabozantinib","deltaMin":10.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3668"},{"comp":"OG000 vs OG001","p":"0.4709"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":46},"locations":{"siteCount":85,"countries":["United States","Australia","Austria","Belgium","France","Germany","Greece","Italy","Japan","Poland","Portugal","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["38552197","34409776"],"seeAlso":["https://forpatients.roche.com/en/trials/cancer/lung-cancer/study-of-atezolizumab-in-combination-with-cabozantinib--77103.html"]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":167},"commonTop":["Diarrhoea","Fatigue","Decreased appetite","Asthenia","Nausea"]}}